Over a 20-year period, French registry data identified that the mortality of patients presenting with ACS substantially decreased, in part due to improved early invasive interventions and newer pharmacologic therapies. From 2010 to 2015, patients presenting with ST-segment elevation ACS demonstrated a 22% reduction in 6-month mortality. However, in patients with NSTE-ACS, 6-month mortality demonstrated a plateau and 3% increase across the same period.1 An updated guideline is useful to review the evidence underpinning recommendations regarding diagnostic test timing, pharmacotherapy, and balancing harms and benefits.
Anchan R, Cifu AS, Paul J. Management of Acute Coronary Syndromes in Patients Without Persistent ST-Segment Elevation. JAMA. 2021;325(15):1556–1557. doi:10.1001/jama.2021.2744
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: